Literature DB >> 19917686

MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation.

Søren E Degn1, Annette G Hansen, Rudi Steffensen, Christian Jacobsen, Jens C Jensenius, Steffen Thiel.   

Abstract

Essential effector functions of innate immunity are mediated by complement activation initiated by soluble pattern recognition molecules: mannan-binding lectin (MBL) and the ficolins. We present a novel, phylogenetically conserved protein, MAp44, which is found in human serum at 1.4 microg/ml in Ca(2+)-dependent complexes with the soluble pattern recognition molecules. The affinity for MBL is in the nanomolar range (K(D) = 0.6 nM) as determined by surface plasmon resonance. The first eight exons of the gene for MAp44 encode four domains shared with MBL-associated serine protease (MASP)-1 and MASP-3 (CUB1-EGF-CUB2-CCP1), and a ninth exon encodes C-terminal 17 aa unique to MAp44. mRNA profiling in human tissues shows high expression in the heart. MAp44 competes with MASP-2 for binding to MBL and ficolins, resulting in inhibition of complement activation. Our results add a novel mechanism to those known to control the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917686     DOI: 10.4049/jimmunol.0902388

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

Review 2.  Complementopathies.

Authors:  Andrea C Baines; Robert A Brodsky
Journal:  Blood Rev       Date:  2017-02-06       Impact factor: 8.250

Review 3.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

4.  Plasma levels of MASP-1, MASP-3 and MAp44 in patients with type 2 diabetes: influence of glycaemic control, body composition and polymorphisms in the MASP1 gene.

Authors:  S S Krogh; C B Holt; R Steffensen; K L Funck; P Høyem; E Laugesen; P L Poulsen; S Thiel; T K Hansen
Journal:  Clin Exp Immunol       Date:  2017-04-20       Impact factor: 4.330

5.  Ficolin-1 Levels in Patients Developing Vasospasm and Cerebral Ischemia After Spontaneous Subarachnoid Hemorrhage.

Authors:  Laura Llull; Steffen Thiel; Sergio Amaro; Álvaro Cervera; Anna M Planas; Ángel Chamorro
Journal:  Mol Neurobiol       Date:  2016-10-12       Impact factor: 5.590

Review 6.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

7.  Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.

Authors:  Vasile I Pavlov; Mikkel-Ole Skjoedt; Ying Siow Tan; Anne Rosbjerg; Peter Garred; Gregory L Stahl
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

8.  Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lectin pathway.

Authors:  Márton Megyeri; Veronika Harmat; Balázs Major; Ádám Végh; Júlia Balczer; Dávid Héja; Katalin Szilágyi; Dániel Datz; Gábor Pál; Péter Závodszky; Péter Gál; József Dobó
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

9.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

10.  Collectin-11/MASP complex formation triggers activation of the lectin complement pathway--the fifth lectin pathway initiation complex.

Authors:  Ying Jie Ma; Mikkel-Ole Skjoedt; Peter Garred
Journal:  J Innate Immun       Date:  2012-12-04       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.